Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance

Critical Care Medicine

Volumn 35, Issue 9 SUPPL., 2007, Pages

  Cree, Melanie G ^a   Aarsland, Asle ^a   Herndon, David N ^a   Wolfe, Robert R ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Burn trauma; Fat oxidation; Insulin resistance; Intracellular insulin signaling; Mitochondrial substrate oxidation; Muscle metabolism; Pediatrics

Indexed keywords

FENOFIBRATE; LIPID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; PLACEBO; TRACER;

BURN; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; GLUCOSE METABOLISM; HUMAN; HYPERMETABOLISM; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID METABOLISM; MITOCHONDRION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SKELETAL MUSCLE; TREATMENT OUTCOME;

BURNS; CRITICAL ILLNESS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLYCEROL; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MITOCHONDRIA; MUSCLE, SKELETAL; PPAR ALPHA;

EID: 34548153333     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000278066.05354.53     Document Type: Conference Paper

References (97)

1. Howard JM: Studies of the absorption and metabolism of glucose following injury: The systemic response to injury. Ann Surg 1955; 141:321-326
2. Frayn KN: Effects of burn injury on insulin secretion and on sensitivity to insulin in the rat in vivo. Eur J Clin Invest 1975; 5:331-337
3. Wolfe RR: Glucose metabolism in burn injury: A review. J Burn Care Rehabil 1985; 6:408-418
4. Little RA, Henderson A, Frayn KN, et al: The disposal of intravenous glucose studied using glucose and insulin clamp techniques in sepsis and trauma in man. Acta Anaesthesiol Belg 1987; 38:275-279
5. Black PR, Brooks DC, Bessey PQ, et al: Mechanisms of insulin resistance following injury. Ann Surg 1982; 196:420-435
6. Nygren J, Thorell A, Efendic S, et al: Site of insulin resistance after surgery: The contribution of hypocaloric nutrition and bed rest. Clin Sci (Lond) 1997; 93:137-146
7. Thorell A, Efendic S, Gutniak M, et al: Development of postoperative insulin resistance is associated with the magnitude of operation. Eur J Surg 1993; 159:593-599
8. Thorell A, Efendic S, Gutniak M, et al: Insulin resistance after abdominal surgery. Br J Surg 1994; 81:59-63
9. Thorell A, Nygren J, Essen P, et al: The metabolic response to cholecystectomy: Insulin resistance after open compared with laparoscopic operation. Eur J Surg 1996; 162:187-191
10. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367
11. Garcia-Avello A, Lorente JA, Cesar-Perez J, et al: Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb Res 1998; 89:59-64
12. Holm C, Horbrand F, Mayr M, et al: Acute hyperglycaemia following thermal injury: Friend or foe? Resuscitation 2004; 60:71-77
13. Gore DC, Chinkes D, Heggers J, et al: Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 2001; 51:540-544
14. Mowlavi A, Andrews K, Milner S, et al: The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 2000; 45:629-632
15. Cuthbertson D: Post-shock metabolic response. Lancet 1942; 1:433-436
16. Wolfe RR: Review: Acute versus chronic response to burn injury. Circ Shock 1981; 8:105-115
17. Hart DW, Wolf SE, Mlcak R, et al: Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312-319
18. Cree MG, Zwetsloot JJ, Herndon DN, et al: Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007; 245:214-221
19. Veening MA, Van Weissenbruch MM, Delemarre-Van De Waal HA: Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J Clin Endocrinol Metab 2002; 87:4657-4661
20. Weiss R, Dufour S, Taksali SE, et al: Prediabetes in obese youth: A syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003; 362:951-957
21. Goodyear LJ, Giorgino F, Sherman LA, et al: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95:2195-2204
22. Carter EA, Burks D, Fischman AJ, et al: Insulin resistance in thermally-injured rats is associated with post-receptor alterations in skeletal muscle, liver and adipose tissue. Int J Mol Med 2004; 14:653-658
23. Ikezu T, Okamoto T, Yonezawa K, et al: Analysis of thermal injury-induced insulin resistance in rodents: Implication of postreceptor mechanisms. J Biol Chem 1997; 272:25289-25295
24. Zhang Q, Carter EA, Ma BY, et al: Molecular mechanism(s) of burn-induced insulin resistance in murine skeletal muscle: Role of IRS phosphorylation. Life Sci 2005; 77:3068-3077
25. Yu C, Chen Y, Cline GW, et al: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-50236
26. Stoner HB, Frayn KN, Barton RN, et al: The relationships between plasma substrates and hormones and the severity of injury in 277 recently injured patients. Clin Sci (Lond) 1979; 56:563-573
27. Harris RL, Frenkel RA, Cottam GL, et al: Lipid mobilization and metabolism after thermal trauma. J Trauma 1982; 22:194-198
28. Enoksson S, Hagstrom-Toft E, Nordahl J, et al: Marked reutilization of free fatty acids during activated lipolysis in human skeletal muscle. J Clin Endocrinol Metab 2005; 90:1189-1195
29. Oscai LB, Essig DA, Palmer WK: Lipase regulation of muscle triglyceride hydrolysis. J Appl Physiol 1990; 69:1571-1577
30. Frayn KN, Little RA, Maycock PF, et al: The relationship of plasma catecholamines to acute metabolic and hormonal responses to injury in man. Circ Shock 1985; 16:229-240
31. Wolfe RR, Herndon DN, Jahoor F, et al: Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987; 317:403-408
32. Aarsland A, Chinkes D, Wolfe RR, et al: Betablockade lowers peripheral lipolysis in burn patients receiving growth hormone: Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Ann Surg 1996; 223:777-787
33. Wolfe RR: Substrate utilization/insulin resistance in sepsis/trauma. Baillieres Clin Endocrinol Metab 1997; 11:645-657
34. Galster AD, Bier DM, Cryer PE, et al: Plasma palmitate turnover in subjects with thermal injury. J Trauma 1984; 24:938-945
35. Cree MG, Newcomer BR, Herndon DN, et al: PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond) 2007; 4:9
36. Padfield KE, Astrakas LG, Zhang Q, et al: Burn injury causes mitochondrial dysfunction in skeletal muscle. Proc Natl Acad Sci U S A 2005; 102:5368-5373
37. Yasuhara S, Perez ME, Kanakubo E, et al: Skeletal muscle apoptosis after burns is associated with activation of proapoptotic signals. Am J Physiol Endocrinol Metab 2000; 279:E1114-E1121
38. Wang XM, Chen KM, Wang Y, et al: Functional changes in rat-liver mitochondria during the early phase of burn injury. Burns Incl Therm Inj 1986; 12:461-464
39. Liang WY, Tang LX, Yang ZC, et al: Calcium induced the damage of myocardial mitochondrial respiratory function in the early stage after severe burns. Burns 2002; 28:143-146
40. Dulloo AG, Samec S, Seydoux J: Uncoupling protein 3 and fatty acid metabolism. Biochem Soc Trans 2001; 29:785-791
41. Herndon DN: Total Burn Care. London, Saunders, 2002
42. Cree MG, Fram RY, Herndon DN, et al: Human mitochondrial oxidative capacity is acutely impaired following burn trauma. FASEB J 2007; 21:A839
43. Rasmussen BB, Holmback UC, Volpi E, et al: Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest 2002; 110:1687-1693
44. Champe P, Harvey R: Lippincott's Illustrated Reviews. Philadelphia, Lippincott Williams & Wilkins, 1994
45. Chung CD, Bieber LL: Properties of the medium chain/long chain carnitine acyltransferase purified from rat liver microsomes. J Biol Chem 1993; 268:4519-4524
46. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992; 15:318-368
47. Bachmann OP, Dahl DB, Brechtel K, et al: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 2001; 50:2579-2584
48. Machann J, Haring H, Schick F, et al: Intramyocellular lipids and insulin resistance. Diabetes Obes Metab 2004; 6:239-248
49. Perseghin G, Scifo P, De Cobelli F, et al: Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: A 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48:1600-1606
50. Pan DA, Lillioja S, Kriketos AD, et al: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997; 46:983-988
51. Goodpaster BH, Krishnaswami S, Resnik H, et al: Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 2003; 26:372-379
52. Ferrannini E, Vichi S, Beck-Nielsen H, et al: European Group for the Study of Insulin resistance (EGIR): Insulin action and age. Diabetes 1996; 45:947-953
53. Perseghin G, Scifo P, Danna M, et al: Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. Am J Physiol Endocrinol Metab 2002; 283:E556-E564
54. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 2001; 50:2337-2343
55. Kautzky-Willer A, Krssak M, Winzer C, et al: Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes 2003; 52:244-251
56. Griffin ME, Marcucci MJ, Cline GW, et al: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48:1270-1274
57. Jucker BM, Rennings AJ, Cline GW, et al: 13C and 31P NMR studies on the effects of increased plasma free fatty acids on intramuscular glucose metabolism in the awake rat. J Biol Chem 1997; 272:10464-10473
58. Boden G, Chen X, Ruiz J, et al: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93:2438-2446
59. Homko CJ, Cheung P, Boden G: Effects of free fatty acids on glucose uptake and utilization in healthy women. Diabetes 2003; 52:487-491
60. Boden G, Lebed B, Schatz M, et al: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50:1612-1617
61. Bajaj M, Suraamornkul S, Kashyap S, et al: Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:4649-4655
62. Worm D, Henriksen JE, Vaag A, et al: Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulindependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 1994; 78:717-721
63. Kelley DE, Simoneau JA: Impaired free fatty acid utilization by skeletal muscle in noninsulin-dependent diabetes mellitus. J Clin Invest 1994; 94:2349-2356
64. Ritov VB, Menshikova EV, He J, et al: Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005; 54:8-14
65. Shulman GI: Unraveling the cellular mechanism of insulin resistance in humans: New insights from magnetic resonance spectroscopy. Physiology (Bethesda) 2004; 19:183-190
66. Hulver MW, Dohm GL: The molecular mechanism linking muscle fat accumulation to insulin resistance. Proc Nutr Soc 2004; 63:375-380
67. Itani SI, Zhou Q, Pories WJ, et al: Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 2000; 49:1353-1358
68. Belfort R, Mandarino L, Kashyap S, et al: Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005; 54:1640-1648
69. Rachek LI, Musiyenko SI, Ledoux SP, et al: Palmitate induced mtDNA damage and apoptosis in L6 rat skeletal muscle cells. Endocrinology 2006; 148:293-299
70. Cree MG, Newcomer BN, Herndon DN, et al: PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond), In Press
71. Astrakas LG, Goljer I, Yasuhara S, et al: Proton NMR spectroscopy shows lipids accumulate in skeletal muscle in response to burn trauma-induced apoptosis. FASEB J 2005; 19:1431-1440
72. Zhang Q, Cao H, Astrakas LG, et al: Uncoupling protein 3 expression and intramyocellular lipid accumulation by NMR following local burn trauma. Int J Mol Med 2006; 18:1223-1229
73. Su JL, Simmons CJ, Wisely B, et al: Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alphaspecific MAbs. Hybridoma 1998; 17:47-53
74. Guerre-Millo M, Gervois P, Raspe E, et al: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275:16638-16642
75. Sugden MC, Greenwood GK, Smith ND, et al: Peroxisome proliferator- activated receptoralpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing and responsiveness. Endocrinology 2003; 144:146-153
76. Lee HJ, Choi SS, Park MK, et al: Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002; 296:293-299
77. Chou CJ, Haluzik M, Gregory C, et al: WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic AZIP/F-1 mice. J Biol Chem 2002; 277:24484-24489
78. Ye JM, Iglesias MA, Watson DG, et al: PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284:E531-E540
79. Ye JM, Doyle PJ, Iglesias MA, et al: Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 2001; 50:411-417
80. Furuhashi M, Ura N, Murakami H, et al: Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and betaoxidation in skeletal muscle. J Endocrinol 2002; 174:321-329
81. Young ME, Goodwin GW, Ying J, et al: Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 2001; 280:E471-E479
82. Frederiksen KS, Wulf EM, Wassermann K, et al: Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptoralpha agonists. J Mol Endocrinol 2003; 30:317-329
83. Minnich A, Tian N, Byan L, et al: A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280:E270-E279
84. Crabb DW, Galli A, Fischer M, et al: Molecular mechanisms of alcoholic fatty liver: Role of peroxisome proliferator-activated receptor alpha. Alcohol 2004; 34:35-38
85. Zhang J, Phillips DI, Wang C, et al: Human skeletal muscle PPARalpha expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity. Am J Physiol Endocrinol Metab 2004; 286:E168-E175
86. Muoio DM, Way JM, Tanner CJ, et al: Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002; 51:901-909
87. Idzior-Walus B, Sieradzki J, Rostworowski W, et al: Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30:871-878
88. Tan CE, Chew LS, Tai ES, et al: Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 2001; 154:469-474
89. Yong QW, Thavintharan S, Cheng A, et al: The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome. Ann Acad Med Singapore 1999; 28:778-782
90. Damci T, Tatliagac S, Osar Z, et al: Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003; 14:357-360
91. Kobayashi M, Shigeta Y, Hirata Y, et al: Improvement of glucose tolerance in NIDDM by clofibrate: Randomized double-blind study. Diabetes Care 1988; 11:495-499
92. Vega GL, Cater NB, Hadizadeh DR III, et al: Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther 2003; 74:236-244
93. Forcheron F, Cachefo A, Thevenon S, et al: Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002; 51:3486-3491
94. Hirosumi J, Tuncman G, Chang L, et al: A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-336
95. Reynoso R, Salgado LM, Calderon V: High levels of palmitic acid lead to insulin resistance due to changes in the level of phosphorylation of the insulin receptor and insulin receptor substrate-1. Mol Cell Biochem 2003; 246:155-162
96. Schrauwen P, Hesselink MK: The role of uncoupling protein 3 in fatty acid metabolism: Protection against lipotoxicity? Proc Nutr Soc 2004; 63:287-292
97. Zhao SP, Wu J: Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 2004; 347:145-150